| Primary |
| Vulvovaginal Dryness |
34.5% |
| Atrophic Vulvovaginitis |
13.3% |
| Menopausal Symptoms |
7.0% |
| Hormone Replacement Therapy |
6.9% |
| Hypertension |
5.1% |
| Blood Cholesterol Increased |
3.7% |
| Menopause |
3.7% |
| Dyspareunia |
3.2% |
| Oestrogen Replacement Therapy |
3.2% |
| Thyroid Disorder |
3.0% |
| Hypothyroidism |
2.5% |
| Vulvovaginal Discomfort |
2.4% |
| Off Label Use |
1.9% |
| Cystitis Interstitial |
1.7% |
| Depression |
1.6% |
| Migraine |
1.5% |
| Diabetes Mellitus |
1.2% |
| Hypersensitivity |
1.2% |
| Pain |
1.2% |
| Vulvovaginal Pruritus |
1.2% |
|
| Drug Ineffective |
22.0% |
| Vulvovaginal Discomfort |
14.0% |
| Vulvovaginal Pain |
9.7% |
| Vulvovaginal Mycotic Infection |
6.4% |
| Fungal Infection |
5.6% |
| Vaginal Haemorrhage |
4.6% |
| Vaginal Infection |
4.4% |
| Vaginal Discharge |
4.3% |
| Vulvovaginal Pruritus |
3.5% |
| Vaginal Odour |
3.1% |
| Vomiting |
2.8% |
| Urinary Tract Infection |
2.6% |
| Vulvovaginal Dryness |
2.5% |
| Nausea |
2.3% |
| Pain |
2.3% |
| Vulvovaginal Burning Sensation |
2.3% |
| Hot Flush |
2.1% |
| Discomfort |
2.0% |
| Dyspareunia |
1.8% |
| Product Quality Issue |
1.6% |
|
| Secondary |
| Hormone Replacement Therapy |
20.9% |
| Vulvovaginal Dryness |
16.1% |
| Menopausal Symptoms |
11.0% |
| Atrophic Vulvovaginitis |
8.8% |
| Menopause |
8.8% |
| Dyspareunia |
5.7% |
| Vulvovaginal Discomfort |
3.4% |
| Vulvovaginal Burning Sensation |
3.0% |
| Vulvovaginal Pruritus |
2.9% |
| Hypertension |
2.6% |
| Blood Cholesterol Increased |
2.3% |
| Cystitis Interstitial |
2.2% |
| Bipolar Disorder |
1.9% |
| Pollakiuria |
1.9% |
| Off Label Use |
1.7% |
| Oestrogen Replacement Therapy |
1.5% |
| Vulvovaginal Pain |
1.5% |
| Bladder Prolapse |
1.2% |
| Hot Flush |
1.2% |
| Depression |
1.1% |
|
| Drug Ineffective |
24.2% |
| Breast Cancer |
16.0% |
| Vulvovaginal Discomfort |
9.4% |
| Vulvovaginal Pain |
9.0% |
| Breast Cancer Female |
6.1% |
| Vaginal Haemorrhage |
4.1% |
| Vulvovaginal Pruritus |
3.7% |
| Vaginal Discharge |
3.3% |
| Vulvovaginal Mycotic Infection |
3.3% |
| Urinary Tract Infection |
2.9% |
| Menorrhagia |
2.0% |
| Pelvic Pain |
2.0% |
| Thrombosis |
2.0% |
| Vision Blurred |
2.0% |
| Cystitis Klebsiella |
1.6% |
| Fungal Infection |
1.6% |
| Product Quality Issue |
1.6% |
| Sleep Disorder |
1.6% |
| Vaginal Erosion |
1.6% |
| Vomiting |
1.6% |
|
| Concomitant |
| Immunodeficiency Common Variable |
10.8% |
| Breast Cancer |
10.1% |
| Breast Cancer Metastatic |
10.1% |
| Osteoporosis |
9.4% |
| Product Used For Unknown Indication |
8.5% |
| Hormone Replacement Therapy |
6.9% |
| Hypertension |
5.5% |
| Irritable Bowel Syndrome |
5.1% |
| Hot Flush |
4.6% |
| Rheumatoid Arthritis |
3.9% |
| Supplementation Therapy |
3.7% |
| Arrhythmia |
3.2% |
| Drug Use For Unknown Indication |
2.5% |
| Migraine |
2.5% |
| Depression |
2.3% |
| Pain |
2.3% |
| Anxiety |
2.1% |
| Constipation |
2.1% |
| Menopause |
2.1% |
| Multiple Sclerosis |
2.1% |
|
| White Blood Cell Count Decreased |
12.5% |
| Tooth Abscess |
7.8% |
| Vaginal Haemorrhage |
7.8% |
| Vomiting |
7.8% |
| Hyponatraemia |
6.3% |
| Osteonecrosis |
6.3% |
| Vascular Anomaly |
6.3% |
| Candidiasis |
4.7% |
| Diarrhoea |
4.7% |
| Weight Increased |
4.7% |
| Anxiety |
3.1% |
| Bladder Disorder |
3.1% |
| Breast Cancer |
3.1% |
| Cervical Dysplasia |
3.1% |
| Depression |
3.1% |
| Drug Ineffective |
3.1% |
| Dyspnoea |
3.1% |
| Empyema |
3.1% |
| Injury |
3.1% |
| Lung Infection |
3.1% |
|
| Interacting |
| Urinary Tract Infection |
22.2% |
| Vaginal Abscess |
22.2% |
| Blood Pressure Increased |
11.1% |
| Hypertension |
11.1% |
| Hypothyroidism |
11.1% |
| Off Label Use |
11.1% |
| Vulvovaginal Dryness |
11.1% |
|
| Breast Pain |
25.0% |
| Diabetes Mellitus |
25.0% |
| Diarrhoea |
25.0% |
| Nausea |
25.0% |
|
